26 / 38
MONARCH 1 (Phase II): Abemaciclib monotherapy in HR+/
HER- BC, after chemotherapy for advanced disease
2L/3L HR+/HER2– mBC
(inc. prior taxane)
N = 132
Abemaciclib 200 mg BID
D1–28
PD
Primary endpoint:
•
Objective response rate (investigator-
assessed)
Key secondary endpoints:
•
Overall survival
•
Duration of response
•
Progression-free survival
Dickler MN, et al. Submitted